Adding docetaxel to androgen deprivation therapy (ADT) plus radiation therapy (RT) failed to improve survival in unfavorable-risk prostate cancer, though the combination may hold benefit for certain ...
In this phase 3 trial, researchers sought to determine whether the combination of ceralasertib plus durvalumab would improve NSCLC outcomes compared to docetaxel.
Pembrolizumab plus docetaxel does not improve radiographic progression-free survival or overall survival compared with docetaxel alone. Adding pembrolizumab to docetaxel is not better than docetaxel ...
Doxetaxel recharge was associated with a 3.3-month benefit in OS and a 1.8-month improvement in time to subsequent treatment or death. Docetaxel rechallenge improved overall survival compared with ...
The role of digital clinical measures in improving cancer care and research. Quartino, A.L et al., 2014. Pharm. Res, 31(12), pp.3390-3403. 5. Crawford, J., et al ...
The phase 3 study, known as Neo-Healer or KN026–004, was an open-label, multicenter trial that randomly assigned ...
The ARASAFE study showed that a 50 mg/m2 biweekly docetaxel regimen reduced severe side effects compared to the standard 75 mg/m2 triweekly regimen in mHSPC patients. The experimental regimen resulted ...
Objective: To assess the efficacy and safety profile of docetaxel, as a single agent, in the treatment of elderly patients with advanced breast cancer. Methods: Twenty-eight patients, with a median ...
CHICAGO -- Germline variations did not predict the risk of taxane-induced peripheral neuropathy (TIPN) in a phase II trial involving Black women with early-stage breast cancer, but the researchers ...
Please provide your email address to receive an email when new articles are posted on . The addition of docetaxel to cisplatin and 5-FU chemotherapy significantly extended OS as neoadjuvant therapy ...
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma Table 1. Characteristics of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results